BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1404 related articles for article (PubMed ID: 2142494)

  • 21. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
    Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
    Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical experience with a triphasic oral contraceptive ('Trinordiol') in young women.
    Gaspard UJ; Deville JL; Dubois M
    Curr Med Res Opin; 1983; 8(6):395-404. PubMed ID: 6406157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pituitary and ovarian function in women receiving hormonal contraception.
    Cohen BL; Katz M
    Contraception; 1979 Nov; 20(5):475-87. PubMed ID: 393456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pulsatile luteinizing hormone patterns in long term oral contraceptive users.
    Hemrika DJ; Slaats EH; Kennedy JC; de Vries Robles-Korsen TJ; Schoemaker J
    J Clin Endocrinol Metab; 1993 Aug; 77(2):420-6. PubMed ID: 8345046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of oral versus transdermal steroidal contraceptives on androgenic markers.
    White T; Jain JK; Stanczyk FZ
    Am J Obstet Gynecol; 2005 Jun; 192(6):2055-9. PubMed ID: 15970897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of a new triphasic oral contraceptive in private practice.
    Ellsworth HS; Ayerst RI; Harris JW; Stone RA; Anderson AE; Jones TL; Curtis MK
    Contraception; 1986 Nov; 34(5):435-42. PubMed ID: 3102161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
    Notelovitz M; Kitchens CS; Khan FY
    Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles.
    Landgren BM; Diczfalusy E
    Contraception; 1984 May; 29(5):437-46. PubMed ID: 6430642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
    Carlström K; Lunell NO; Zador G
    Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women.
    Nader S; Riad-Gabriel MG; Saad MF
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3074-7. PubMed ID: 9284746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum.
    Kuhnz W; Baumann A; Staks T; Dibbelt L; Knuppen R; Jütting G
    Contraception; 1993 Oct; 48(4):303-22. PubMed ID: 8222659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sex hormone binding globulin: effect of synthetic steroids on the assay and effect of oral contraceptives.
    Bowles SM; Mills RJ
    Ann Clin Biochem; 1981 Jul; 18(Pt 4):226-31. PubMed ID: 7197136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term profile of a new progestin.
    Lippman J
    Int J Fertil; 1992; 37 Suppl 4():218-22. PubMed ID: 1362189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
    Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
    Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two oral contraceptives, efficacy, serum proteins, and lipid metabolism. A comparative multicentre study on a triphasic and a fixed dose combination.
    Cullberg G; Samsioe G; Andersen RF; Bredesgaard P; Andersen NB; Ernerot H; Fanøe E; Fylling P; Haack-Sørensen PE; Klottrup P; Pedersen JH; Sandager T
    Contraception; 1982 Sep; 26(3):229-43. PubMed ID: 6217028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
    Falsetti L; Galbignani E
    Contraception; 1990 Dec; 42(6):611-9. PubMed ID: 2150631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sex hormone profiles in oligomenorrheic adolescent girls and the effect of oral contraceptives.
    Siegberg R; Nilsson CG; Stenman UH; Widholm O
    Fertil Steril; 1984 Jun; 41(6):888-93. PubMed ID: 6233177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized cross-over study on various hormonal parameters of two triphasic oral contraceptives.
    Aden U; Jung-Hoffmann C; Kuhl H
    Contraception; 1998 Aug; 58(2):75-81. PubMed ID: 9773261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative evaluation of the androgenicity of four low-dose, fixed-combination oral contraceptives.
    Coenen CM; Thomas CM; Borm GF; Rolland R
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():92-7. PubMed ID: 8574256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum.
    Kuhnz W; Staks T; Jütting G
    Contraception; 1994 Dec; 50(6):563-79. PubMed ID: 7705098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 71.